Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 18/20 | 0.79 |
| ▸ | MAPK12 | P53778 | 18/20 | 0.79 |
| ▸ | MAPK11 | Q15759 | 18/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 18/20 | 0.79 |
| ▸ | JAK2 | O60674 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13791346 | 0.89 | MAPK14 (0.79) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1012719 | 0.89 | MAPK13 (0.78) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL28942120 | 0.88 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL25793170 | 0.86 | MAPK13 (0.74) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL18655321 | 0.86 | MAPK13 (0.73) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL5164195 | 0.85 | CDK8 (0.80) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| Hydrochloric Acid SCHEMBL29397175 | 0.84 | CDK8 (0.78) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL3187040 | 0.83 | MAPK14 (0.73) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL27640941 | 0.83 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL18324914 | 0.82 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9820976-B2 | 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-11-21 | — | — | US | disclosed |
| US-20170079963-A1 | 1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-03-23 | — | — | US | disclosed |
| US-9439893-B2 | 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-09-13 | — | — | US | disclosed |
| US-20160030405-A1 | 1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170079963-A1 | 1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY | KRAS, NRAS, HRAS | MAPK13 247/4885MAPK12 362/4885MAPK11 262/4885 |
| US-20160030405-A1 | 1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY | KRAS, NRAS, HRAS | MAPK13 247/4885MAPK12 362/4885MAPK11 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.